| Brand Name | Alecensa |
| Packaging Type | Bottle |
| Molecule | Alectinib |
| Generic Name | Alectinib 150mg |
| Manufactured By | Roche Pharmaceuticals |
| Quantity | 240 Capsules |
| Form | Capsule |
| Country of Origin | Switzerland |
| Categories | Oncology |
Alectinib 150 mg is primarily used to treat non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. It is used in patients who have already received prior treatment with chemotherapy or other ALK inhibitors.
Alectinib has shown positive results in extending progression-free survival in patients with ALK-positive NSCLC. However, life expectancy depends on several factors, including the stage of cancer, response to treatment, and overall health. The exact prognosis should be discussed with an oncologist based on individual health conditions and responses to treatment.
Alectinib is not considered chemotherapy. It is a targeted therapy that specifically inhibits the ALK protein in cancer cells, making it a type of targeted cancer treatment.
Yes, alectinib has been shown to shrink tumors in patients with ALK-positive non-small cell lung cancer (NSCLC). It works by inhibiting the ALK protein that drives the growth of cancer cells, leading to tumor reduction or stabilization in many patients.
Yes, a prescription is required for alectinib 150 mg. It is a prescription-only medication used for the treatment of specific types of cancer, and it should be prescribed by an oncologist after evaluating the patient's condition.
